US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer. - Wikidata - wikimedia - TriplyDB

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

http://www.wikidata.org/entity/Q34974208

about

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.Breast cancer multigene testing trends and impact on chemotherapy use.21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.

P2860

Q26861418-CCE6D374-86E7-4F25-9640-E53733DC85AB Q30252422-37FD14B7-B28E-4945-A9D8-9115C1FB2045 Q34171119-096369BD-7E1A-43D2-80E1-FA6464817F50 Q36424052-DE0F6F7F-5B42-46F4-94BD-888EF097DFE1 Q37008507-78E6753D-5B99-4DCB-BF0D-018A40F7E201 Q37083264-B6DFD190-108A-4C81-9DFC-2806803EC3B4 Q37138266-2AFB0A44-39D3-46DE-A2EE-6C29F603A815 Q37383276-D4BA2D39-68E5-40C0-8EA7-48026091C99A Q38024305-5D9BA542-5442-4136-8044-789F8EE14304 Q38272730-82EE49F8-82DD-463D-AF83-F3AAB60FA9A1 Q39187437-C22BF406-2410-4BDF-9524-F68194173BCC Q40124991-681BEB13-6438-4412-AF9E-A57D52928932 Q40808798-E91BC253-5004-402D-9E1B-4C4E649C29EF Q48225891-DC2B60BE-DFE0-46EE-8232-098BAD48253F Q52585073-365E11E0-050A-49CF-A0CD-8BFD78C63772 Q52586260-CDE2B87D-4BB3-4EDD-9EE0-9CCCCD366B72

P2860

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

http://www.wikidata.org/entity/Q34974208

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@ast

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@en

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@nl

type

label

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@ast

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@en

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@nl

prefLabel

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@ast

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@en

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@nl

P1433

Q34974208-B9FE26ED-57A3-4440-BCE3-3D6F1E661D6D

P1476

Q34974208-A47898A9-43D4-4599-ABBD-DBC6B70159A0

P2093

Q34974208-0FDF0E66-4818-4E71-9B62-A29CF8205A99

Q34974208-630ABC10-B958-4283-8671-DA948E8F7192

Q34974208-8F9934C9-5A1B-4FB0-AC21-7B7C7E017D0E

Q34974208-8FA76163-F1A0-42F3-ABE7-F1F00666087B

P2860

Q34974208-0A0E3F66-4508-43BA-BF96-1FF753C84279

Q34974208-2AA1C04B-4024-48C5-B355-B6444A8E004F

Q34974208-3B673941-639F-45CC-8F82-AA86E22B82A7

Q34974208-403A9364-8983-4854-91C2-3CF3C62A7575

Q34974208-49BAAC1F-BA60-477D-B03C-1DFB4AA6C287

Q34974208-5C3FB688-FBD0-4C9F-9394-762FA15A1D43

Q34974208-6857A19B-4201-4DED-8C47-C4FD899EE051

Q34974208-724D1927-0E7E-4485-AE18-DA50A271654E

Q34974208-7401B155-AE27-4712-8E96-B7C97E0C2A21

Q34974208-7530D12B-7DED-47FB-927A-B0479754248F

P304

Q34974208-E2FD7EF8-5920-448A-B827-EB6CDC02195A

P31

Q34974208-4D529348-D9CE-4660-8F86-066B75F4E73F

P356

Q34974208-D0567FE1-AB4F-43C7-9950-48341190E6E4

P407

Q34974208-870C6EBB-22CA-4309-B206-190275E4C527

P433

Q34974208-4E8FEAC5-91B7-425A-B781-E9E6611403C4

P478

Q34974208-83536AEF-82B9-4EF1-8D64-C3D89B155E73

P577

Q34974208-6623FE22-F149-40F9-A9F9-E039CE32F916

P698

Q34974208-CB7381EB-10A0-4E6F-BC23-2B72819CEDA5

P932

Q34974208-1203C71F-9427-42A5-A33F-85A479C1EAF4

P356

JOP.2011.000303

P1433

Journal of Oncology Practice

P1476

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.

@en

P2093

John Hornberger

http://www.w3.org/2001/XMLSchema#string

Katie Krebs

http://www.w3.org/2001/XMLSchema#string

Louis Hochheiser

http://www.w3.org/2001/XMLSchema#string

Rebecca Chien

http://www.w3.org/2001/XMLSchema#string

P2860

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.

Adjuvant chemotherapy in older women with early-stage breast cancer.

Evaluation of trends in the cost of initial cancer treatment

Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

P304

e38s-45s

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JOP.2011.000303

http://www.w3.org/2001/XMLSchema#string

P407

P433

3 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21886510

http://www.w3.org/2001/XMLSchema#string

P932

3092466

http://www.w3.org/2001/XMLSchema#string